Did You Know?

Editor’s Picks

Latest News

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media ReleaseCOPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early...

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

Sublingual Compounded Vardenafil, Sildenafil, Tadalafil, and Apomorphine for Prescription ED Treatment: 10-Minute Onset and 36-Hour Active Window ResearchedKennewick, WA, June...

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effectsNew analyses showed patients...

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat...

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of up to 89.2% at 24...

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage...

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1...

error: Content is protected !!